Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity.

Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI). As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI), most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH), the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders.

POSITION SUMMARY

Provide critical leadership and above-country market access strategies including core disease models, value stories, global pricing, economic modeling, and input into Clinical Development programs.
Work closely with Medical Affairs colleagues, Organized customers and Distribution providers to identify real-world and patient quality of life data capture / evidence value solutions and publication opportunities.
Monitors healthcare legislative trends, understands healthcare policies, assesses implications of policies, and develops reimbursement strategies that address barriers to provider and patient access.
Understands total cost of care and all aspects of reimbursement (coverage, coding, and payment) for outpatient and inpatient settings across multiple payer segments.
Support the formulation of a clear and compelling disease and product value propositions through the creation of payer engagement (AMCP Dossier, Value and Economic Prop.), and provider / patient reimbursement support tools.
Monitor the competition to understand how the evolving market will impact current and future market access strategies.
Identify and develop pricing recommendations, coding and reimbursement strategies for current and pipeline assets that will support future Pricing and Reimbursement decisions in the US and other key Ex-US markets.
Engage to support the advancement of ICD-10 CM coding initiatives, and product-specific HCPCS coding application.
Identify product market access risks and opportunities, incorporate them into pipeline product strategies and reflect them in identified Target Product Profiles.
Identify pricing and reimbursement analogues to support value and access decisions.
Create payer materials for branded and unbranded disease awareness campaigns.
Support the identification, creation of defensible, performance driven, quality / outcomes or risked based product / portfolio contract, or rebate opportunities.
Manage agency relationships and contracts to deliver tools/tactics/resources, and ensure on time delivery, that is aligned with the departmental budget.
Provide subject matter expertise to the broader organization, including competitive and product coverage access intelligence, healthcare reform, landscape trends, and pull-through initiatives. This includes cross-functional support of corp. training initiatives, content, tools and presentation development in partnership with Training and Cross-Departmental leaders.
Represent Rezolute at Key Industry Conferences (e.g. AMCP, PCMA, ISPOR, Asembia, etc.).
Ensure that all activities and interactions are carried out with the highest ethical and professional standards, and that all work is accomplished with quality and in accordance with Rezolute values.
Manage/recruit in-house or contracted payer account team to educate key payers using PIE (Payer Information Exchange) before approval and PVP (Payer Value Proposal) after the approval
Educate payers on the label and influence them to develop policies based on the label and/or clinical trial exclusion criteria
Resolve rejection/prior authorization issues by closely working with the payers and patients support services team and hub in a timely manner

QUALIFICATIONS

Experience with rare/orphan drugs is required. Therapeutic area experience is a plus.
Product launch experience is required, and company start-up experience is preferred.
Familiarity with current legal and regulatory landscape pertinent to the pharmaceutical/biotechnology industry.
Strong analytical capabilities, with working knowledge of government pricing practices (calculations methodologies, HTA, healthcare programs, and supporting regulations), and trade systems and processes.
Demonstrated flexibility to adapt to a changing environment, implement creative solutions to complex problems, and ability to function in a project leadership role.
Ability to develop and maintain strong internal and external relationships, including direct collaboration with vendors and other third parties.
Superior interpersonal, oral and written communication, and presentation skills, with great attention to detail.
Leads with strong business acumen and a compliance mindset.
Passionate about patients and building a new commercial organization.
Advanced Microsoft Excel, Word and PowerPoint skills.

PREFERRED EXPERIENCE, EDUCATION, CERTIFICATIONS, LICENSES:

Minimum Bachelor’s degree required; sciences or business preferred, advanced degree related medical, health economics, health outcomes research, or epidemiology (MS, MBA, MPH, MD/DO, PhD, PharmD) preferred.
Minimum of 10 years of overall industry experience in biotech or pharmaceuticals (i.e. market access and reimbursement, sales, sales management, marketing, training, sales operations, or healthcare / life sciences consulting).
5 years of US market access and reimbursement experience required, with Global and/or international experience preferred. This includes, HTA, US Payer, Patient and Provider access, HEOR, and medical benefit reimbursement coding expertise.

Rezolute (RZLT) currently anticipates the base salary for the Executive Director, Payer Strategy and Engagement role could range from $290,000 to $320,000 and will depend, in part, on the successful candidate’s geographical location and their qualifications for the role, including education and experience. This position will also be eligible for an annual performance bonus in accordance with the terms of the applicable plan (depending, in part, on company and individual performance and at the Company’s discretion on an individual basis). The compensation described above is subject to change and could be higher or lower than the range described based on current market survey data and the qualifications, education, experience and geographical location of the selected candidate.

This role is based in the home office and requires minimum of 3 days per week in the office.

Qualifying employees are eligible to participate in benefit programs such as:

Health Insurance (Medical / Dental / Vision)
Disability, Life & Long-Term Care Insurance
Holiday Pay
Tracking Free Vacation Program
401(k) Plan Match
Educational Assistance Benefit
Fitness Center Reimbursement

We are an Equal Opportunity Employer and do not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class.

About the company

Rezolute Bio develops therapies for rare diseases, aiming to address unmet needs in both pediatric and adult patients. Its lead candidate, RZ358, is a human monoclonal antibody in late-stage trials for congenital hyperinsulinism and works by binding to and inhibiting insulin to reduce hypoglycemic events. The company also pursues RZ402, an oral plasma kallikrein inhibitor for diabetic macular edema. Its goal is to bring approved therapies to patients by advancing late-stage programs toward commercialization and building a portfolio focused on rare diseases.

Company Size

51-200

Company Stage

IPO

Headquarters

Louisville, Kentucky

Founded

2010

Get referred to Rezolute Bio

See people who can refer or advise you

Simplify's Take

What believers are saying

PES 2026 analyses showed CGM hypoglycemia reductions above 50% versus placebo.
FDA accepted tumor HI development streamlining in September 2025, with topline data expected 2H 2026.
Cash and investments reached $120.3 million on March 31, 2026, supporting runway.

What critics are saying

SunRIZE missed primary and key secondary endpoints in December 2025, damaging approval odds.
FDA requested broader sunRIZE and extension datasets on March 17, 2026, delaying filing.
A December 2025 layoff cut 29 employees after the setback, signaling fragile execution.

What makes Rezolute Bio unique

Ersodetug targets insulin receptor signaling, addressing congenital and tumor hyperinsulinism downstream.
FDA granted Breakthrough Therapy Designation for congenital HI on January 7, 2025.
Rezolute paired ersodetug with commercial hires from Ultragenyx and Cytokinetics in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Disability Insurance
Life Insurance
Paid Holidays
Paid Vacation
401(k) Plan Match
Gym Membership

Growth & Insights and Company News

6 month growth

-5%

1 year growth

2 year growth

-1%

Africa Business Watch

Jul 21st, 2026

Rezolute to participate in the BTIG Virtual Biotechnology Conference.

Rezolute to participate in the BTIG Virtual Biotechnology Conference. REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative. About Rezolute, Inc. Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI). The Company's antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com. Rezolute Contacts: Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

The Manila Times

Apr 21st, 2026

Rezolute to present results from its Phase 3 sunRIZE study in congenital hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting.

Rezolute to present results from its Phase 3 sunRIZE study in congenital hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting. By GlobeNewswire April 21, 2026 Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that results from the Phase 3 sunRIZE study of ersodetug in congenital HI were accepted for an oral presentation at the Pediatric Endocrine Society (PES) Annual Meeting being held April 30-May 3, 2026, in San Francisco, CA. In addition to the previously reported topline results, the presentation will also include results from pre-specified and post-hoc sunRIZE analyses, which the Company believes continue to demonstrate target engagement and the therapeutic benefit of ersodetug. Presentation Title: Top-Line Results From a Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (sunRIZE) Format: Oral presentation Presenter: Diva D. De León-Crutchlow, MD, MSCE Session Date and Time: Friday, May 1, 2026, from 8:15 a.m. - 9:15 a.m. PT Session Title: Oral Abstracts #1 About sunRIZE The Phase 3 sunRIZE study (RZ358-301) was a multi-center, randomized, double-blind, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug in patients with congenital hyperinsulinism (HI), ages 3 months to 45 years old, who were experiencing continued hypoglycemia on currently available standard of care (SOC). Eligible participants were randomized to one of three treatment arms to receive either ersodetug (5 or 10 mg/kg) or matched placebo-control as add on to existing SOC. Study drug was administered every other week during an initial loading phase, and then every 4 weeks during the 6-month controlled pivotal treatment period. Following the pivotal treatment phase of the study, participants could roll-over into an optional open-label extension phase to continue to receive ersodetug. The study enrolled 63 participants in more than a dozen countries around the world, inclusive of U.S. patients. The primary and key secondary efficacy endpoints in the study were the change from baseline in the average number of hypoglycemia events per week and the average percent time in hypoglycemia, respectively, over six months of treatment. About Ersodetug Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Forward-Looking Statements This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to, the potential efficacy of ersodetug in treating hypoglycemia. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in Rezolute's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the U.S. Securities and Exchange Commission's website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. Rezolute Contacts: Christen Baglaneas 508-272-6717 Carrie McKim 336-608-9706

The Manila Times

Mar 4th, 2026

Rezolute to Participate in the Citizens Life Sciences Conference

Rezolute to participate in the Citizens Life Sciences Conference. By GlobeNewswire March 4, 2026 REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Citizens Life Sciences Conference, taking place March 10-11, 2026, in Miami, FL. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Citizens representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Rezolute Contacts: Christen Baglaneas 508-272-6717 Carrie McKim powered by 336-608-9706

Rezolute, Inc.

Feb 4th, 2026

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rezolute to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026. February 04, 2026 7:00 am EST Download as PDF REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com. Released February 4, 2026

Fierce Pharma

Aug 21st, 2025

Rezolute resolves commercial question, hiring ex-Ultragenyx exec to ready for rare disease launch

Karnawat joins Rezolute from Cytokinetics, where he spent just over a year as vice president of global value, access and distribution.

Rezolute Bio

Executive Director - Payer Strategy and Engagement, Tumor HI Program

About the job